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Abstract
Alzheimer’s Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the pathophysiol-
ogy of which is very complex and largely unknown. Event-based modeling (EBM) is a data-driven technique
to estimate the sequence in which biomarkers for a disease become abnormal based on cross-sectional data.
It can help in understanding the dynamics of disease progression and facilitate early diagnosis and prognosis
by staging patients. In this work we propose a novel discriminative approach to EBM, which is shown to be
more accurate than existing state-of-the-art EBM methods. The method first estimates for each subject an
approximate ordering of events. Subsequently, the central ordering over all subjects is estimated by fitting
a generalized Mallows model to these approximate subject-specific orderings based on a novel probabilistic
Kendall’s Tau distance. We also introduce the concept of relative distance between events which helps in cre-
ating a disease progression timeline. Subsequently, we propose a method to stage subjects by placing them
on the estimated disease progression timeline. We evaluated the proposed method on Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data and compared the results with existing state-of-the-art EBM meth-
ods. We also performed extensive experiments on synthetic data simulating the progression of Alzheimer’s
disease. The event orderings obtained on ADNI data seem plausible and are in agreement with the current
understanding of progression of AD. The proposed patient staging algorithm performed consistently better
than that of state-of-the-art EBM methods. Event orderings obtained in simulation experiments were more
accurate than those of other EBM methods and the estimated disease progression timeline was observed to
correlate with the timeline of actual disease progression. The results of these experiments are encouraging
and suggest that discriminative EBM is a promising approach to disease progression modeling.
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1. Introduction
Dementia is considered a major global health
problem as the number of people living with de-
mentia was estimated to be about 46.8 million in
2015. It is expected to increase to 131.5 million
in 2050 (Prince et al., 2015). Alzheimer’s Dis-
ease (AD) is the most common form of demen-
tia. There is a gradual shift in the definition
of AD from it being a clinical-pathologic entity
(based on clinical symptoms), to a biological one
based on neuropathologic change (change of imag-
ing and non-imaging biomarkers from normal to ab-
normal) (Jack et al., 2018). The latter definition is
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more useful for understanding the mechanisms of
disease progression.
Preventive and supportive therapy for patients
at risk of developing dementia due to AD could im-
prove their quality of life and reduce costs related
to care and lifestyle changes. To identify the at-
risk individuals as well as monitor the effectiveness
of these preventive and supportive therapies, meth-
ods for accurate patient staging (estimating the dis-
ease severity in each individual) are needed. To
enable accurate patient staging in an objective and
quantitative way, it is important to understand how
the different imaging and non-imaging biomarkers
progress after disease onset.
Longitudinal models of disease progression re-
construct biomarker trajectories in individual sub-
jects (Donohue et al., 2014; Sabuncu et al., 2014;
Schmidt-Richberg et al., 2016). However, the util-
ity of such models is restricted by the fact that lon-
gitudinal data in large groups of patients is scarce.
Identifying at-risk individuals for clinical trials by
studying their biomarker trajectory evolution is
also not feasible.
To circumvent this problem, methods to infer the
order in which biomarkers become abnormal during
disease progression based on cross-sectional data
have been proposed (Fonteijn et al., 2012; Huang
and Alexander, 2012; Iturria-Medina et al., 2016).
The model used in Iturria-Medina et al. (2016) re-
lies on stratification of patients into several sub-
groups based on symptomatic staging, for inferring
the aforementioned ordering. However, the problem
with using symptomatic staging is that it is very
coarse and qualitative. The models used in Fonteijn
et al. (2012); Huang and Alexander (2012) are vari-
ants of Event-Based Models (EBM). EBM algo-
rithms neither rely on symptomatic staging nor on
the presence of longitudinal data for inferring the
temporal ordering of events, where an event is de-
fined by a biomarker becoming abnormal. Figure 1
shows these biomarker events on hypothetical tra-
jectories as expected in a typical neuropathologic
change.
An important assumption made in Fonteijn et al.
(2012) is that the ordering of events is common for
all the subjects in a dataset. AD is known to be
a heterogeneous disease with multiple disease sub-
types. The assumptions in Fonteijn’s EBM may
therefore be too restrictive. The assumptions in
Huang’s EBM on the other hand are more realis-
tic, as they do assume that the disease is heteroge-
neous. However the algorithm does not scale well
Figure 1: Illustration of the output expected in an EBM. The
biomarker trajectories shown here are hypothetical trajecto-
ries representing a change of biomarker value from normal
state. The dots on these trajectories are biomarker events
as defined in an EBM. Output of an EBM is the ordering of
such events.
to a large number of biomarkers (Venkatraghavan
et al., 2017).
To make EBM more scalable to large number of
biomarkers and subjects, as well as make it robust
to variations in ordering, we propose a novel ap-
proach to EBM, discriminative event-based model
(DEBM), for estimating the ordering of events2.
We also introduce the concept of relative distance
between events which helps in creating a disease
progression timeline. Subsequently, we propose a
method to stage subjects by placing them on the
estimated disease progression timeline. The other
contributions of this paper include an optimization
technique for Gaussian mixture modeling that helps
in accurate estimation of event ordering in DEBM
as well as improving the accuracies of other EBMs,
and a novel probabilistic distance metric between
event orderings (probabilistic Kendall’s Tau).
The remainder of the paper is organized as fol-
lows: An introduction to the existing EBM mod-
els is given in Section 2. In Section 3, we propose
our novel method for estimating central ordering of
events. We perform extensive sets of experiments
on ADNI data as well as on simulation data, the
details of which are in Section 4. Section 5 sum-
marizes the results of the experiments. Section 6
discusses the implications of these findings followed
by concluding remarks in Section 7.
2An earlier version of the model was presented at the
IPMI conference (Venkatraghavan et al., 2017). In the cur-
rent manuscript, several methodological improvements and
extensions are presented, and the experimental evaluation
has been expanded substantially.
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2. Event-Based Models
EBM assumes monotonic increase or decrease of
biomarker values with increase in disease sever-
ity (with the exception of measurement noise). It
considers disease progression as a series of events,
where each event corresponds to a new biomarker
becoming abnormal. Fonteijn’s EBM (Fonteijn
et al., 2012) finds the ordering of events (S) such
that the likelihood that a dataset was generated
from subjects following this event ordering is max-
imized. S is a set of integer indices of biomarkers,
which represents the order in which they become
abnormal. Thus, disease progression is defined by
{ES(1), ES(2), ..., ES(N)}, where N is the number of
biomarkers per subject in the dataset and ES(i) is
the i-th event that is associated with biomarker S(i)
becoming abnormal.
In a cross-sectional dataset (X) of M subjects,
Xj denotes a measurement of biomarkers for sub-
ject j ∈ [1,M ], consisting of N scalar biomarker
values xj,i. Probabilistic formulation of an EBM,
as proposed in Fonteijn et al. (2012), can be given
by argmaxS(p(S|X)), where p(S|X) can be written
using Bayes’ rule as:
p(S|X) = p(S)p(X|S)
p(X)
(1)
An important assumption in Fonteijn et al. (2012)
is that p(S) is uniformly distributed. This makes
inferring S, equivalent to the maximum likelihood
problem of maximizing p (X|S)3 . This can be fur-
ther written in terms of Xj as follows:
p (X|S) =
M∏
j=1
p (Xj |S) (2)
where p (Xj |S) can be written as:
p (Xj |S) =
N∑
k=0
p(k|S)p (Xj |k, S) (3)
where p(k|S) is the prior probability of a subject
being at position k of the event ordering, which
is assumed to be equal for each position. The
3Fonteijn’s EBM uses Markov Chain Monte Carlo
(MCMC) sampling to estimate the posterior distribution
P (S|X). Average position of events in all the MCMC sam-
ples was used as a way for selecting the mean ordering by
Fonteijn et al. (2012) whereas further extensions of the work
such as Young et al. (2014) prefer the maximum likelihood
solution.
k which maximizes p (Xj |S) denotes subject j’s
disease stage. This method of identifying disease
severity for a subject results in discrete set of stages,
where the number of stages is one more than the
number of biomarkers used for creating the model.
p (Xj |k, S) can be expressed as:
p (Xj |k, S) =
k∏
i=1
p
(
xj,S(i)|ES(i)
)×
N∏
i=k+1
p
(
xj,S(i)|¬ES(i)
)
(4)
where p
(
xj,S(i)|ES(i)
)
is the likelihood of observing
xj,S(i) in subject j, conditioned on event i having
already occurred. p
(
xj,S(i)|¬ES(i)
)
, on the other
hand, computes a similar likelihood, given that
event i has not occurred.
With the assumption that all the biomarkers
in the control population are normal and that
the biomarker values follow a Gaussian distribu-
tion, p
(
xj,S(i)|¬ES(i)
)
is computed. Abnormal
biomarker values in the patient population are as-
sumed to follow a uniform distribution but not all
biomarkers of a patient could be assumed to be ab-
normal. For this reason, the likelihoods were ob-
tained using a mixture model of a Gaussian and a
uniform distribution, where only the parameters of
the uniform distribution were allowed to be opti-
mized.
This method was modified in Young et al. (2014)
to estimate the optimal ordering in a sporadic AD
dataset with significant proportions of controls ex-
pected to have presymptomatic AD (Schott et al.,
2010). A Gaussian distribution was used to de-
scribe both the control and patient population, and
the mixture model allowed for optimization of pa-
rameters for the Gaussians describing both con-
trol and patient population. The Gaussian mixture
model was also used to incorporate more subjects
from the dataset with clinical diagnosis of mild cog-
nitive impairment (MCI).
After obtaining the central ordering S which
maximizes the likelihood p (X|S), staging of pa-
tients is done by finding a disease stage k for subject
j, such that p (Xj |k, S) is maximized.
The assumption that subjects follow a unique
event ordering was relaxed by Huang and Alexander
(2012), who estimate a distribution of event order-
ings with a central event ordering (S) and a spread
(φ) as per a generalized Mallows model (Fligner and
3
Figure 2: Overview of the steps in DEBM. A) Biomark-
ers measured from different subjects are converted to prob-
abilities of abnormality for individual biomarkers. This is
done by estimating normal and abnormal distributions us-
ing Gaussian mixture modeling before classifying individual
biomarkers using a Bayesian classifier. B) Subject-specific
orderings of biomarker abnormalities are inferred from these
probabilities which are then used to estimate the central or-
dering and for creating the disease progression timeline. C)
This is then used to stage subjects based on disease severity.
Verducci, 1988) using an expectation maximization
algorithm. The E-step estimates the likelihood of
patients’ biomarker value measurements following
subject-specific event order sj , given S and φ. In
the M-step, S and φ are estimated based on sj es-
timated in the E-step. This is done iteratively to
maximize the likelihood of generation of patients’
data based on S and φ. Patient staging in Huang’s
EBM is also a maximum likelihood estimate, but
unlike Fonteijn’s EBM, the staging is done on the
subject-specific event ordering sj .
In both Fonteijn’s and Huang’s EBM, relative
distances between events, that can be observed in
Figure 1, are not captured4. Some events can be
closer to each other than others and using these
relative distance between events could help create
a more informative disease progression model.
3. Discriminative Event-Based Model
Fonteijn’s and Huang’s EBM are generative mod-
els where the likelihood p (X|S) is maximized.
4 Fonteijn et al. (2012) briefly mention the idea of captur-
ing relative distance between events, but it was not validated
or used in any of the experiments.
Huang’s EBM also estimates subject-specific order-
ing based on a generative approach. Here, we pro-
pose our novel method for estimating central or-
dering of events (S), a discriminative event-based
model (DEBM).
The proposed framework is discriminative in na-
ture, since we estimate sj directly based on the pos-
terior probabilities of individual biomarkers becom-
ing abnormal. We also introduce a new concept of
relative distance between events. This subsequently
leads to a novel continuous patient staging algo-
rithm. Figure 2 shows the different steps involved
in our approach.
In Section 3.1, we present the method to robustly
estimate biomarker distributions in pre-event and
post-event classes, given a single cross-sectional
measurement of biomarkers. In Section 3.2, we
present a way for estimating sj , and we address
the problem of estimating a disease timeline from
noisy estimates of sj . In Section 3.3, we present the
continuous patient staging method.
3.1. Biomarker Progression
In this section, we propose a method to robustly
convert xj,i to p (Ei|xj,i), which denotes the pos-
terior probability of a biomarker measurement be-
ing abnormal. Assuming a paradigm similar to
that in previous EBM variants (Huang and Alexan-
der, 2012; Young et al., 2014), the probability den-
sity functions (PDF) of pre-event (p (xj,i|¬Ei)) and
post-event (p (xj,i|Ei)) classes in the biomarkers are
assumed to be represented by Gaussians, indepen-
dently for each biomarker. There are two reasons
why constructing these PDFs is non-trivial. Firstly,
the labels (clinical diagnoses) for the subjects do
not necessarily represent the true labels of all the
biomarkers extracted from the subject. Not all
biomarkers are abnormal for subjects with AD di-
agnosis, while some of the cognitively normal (CN)
subjects could have undiagnosed pre-symptomatic
conditions. Secondly, the clinical diagnosis can be
non-binary and include classes such as MCI, with
significant number of biomarkers in normal and ab-
normal classes.
In our approach we address these two issues in-
dependently. We make an initial estimate of the
PDFs using biomarkers from easily classifiable CN
and easily classifiable AD subjects and later refine
the estimated PDF using the entire dataset.
A Bayesian classifier is trained for each biomarker
using CN and AD subjects, based on the assump-
tion that there are no biomarkers in the pre-
4
symptomatic stage for CN subjects and all the
biomarkers are abnormal for AD subjects. This
classifier is subsequently applied to the training
data, and the predicted labels are compared with
the clinical labels. The misclassified data in the
dataset could either be outliers in each class result-
ing from our aforementioned assumption or could
genuinely belong to their respective classes and rep-
resent the tails of the true PDFs. Irrespective of the
reason of misclassification, we remove them for ini-
tial estimation of the PDFs. This procedure thus
results, for each biomarker, in a set of easily classi-
fiable CN subjects (whose biomarker values repre-
sent normal values) and easily classifiable AD sub-
jects (whose biomarker values represent abnormal
values). This is shown in the top part of Figure 3.
As we use Gaussians to represent the PDFs, we
calculate initial estimates for mean and standard
deviation for both normal (µ¬Ei , σ
¬E
i ) and abnor-
mal classes (µEi , σ
E
i ) based on ‘easy’ CN and ‘easy’
AD subjects for each biomarker i. As these means
and standard deviations are estimated based on
truncated Gaussians, these are biased estimates.
The initial estimates of standard deviations are al-
ways smaller than the expected unbiased estimates
whereas the initial estimates of means are underes-
timated for Gaussians with smaller means (as com-
pared to the other class for corresponding biomark-
ers) and overestimated for Gaussians with larger
means.
We refine the initial estimates using a Gaussian
mixture model (GMM) and include all the avail-
able data, including MCI subjects and previously
misclassified cases. To obtain a robust GMM fit,
a constrained optimization method is used, with
bounds on the means, standard deviations and mix-
ing parameters, based on the aforementioned rela-
tionship between the initial estimates and their cor-
responding expected unbiased estimates. The ob-
jective function for optimization for biomarker i is
a summation of log-likelihoods, for all subjects:
Ci =
∑
∀j
log f(xj,i) (5)
where the likelihood function f(xj,i) is computed as
a function of mixing parameters (θEi , θ
¬E
i ) for the
groups corresponding to post-event and pre-event
respectively and their corresponding Gaussian dis-
tributions (µEi , σ
E
i ) and (µ
¬E
i , σ
¬E
i ):
Figure 3: Overview of the steps involved in the proposed
Gaussian Mixture Model optimization strategy. A) Illustra-
tion of the initialization step for Gaussian Mixture Model.
Rejecting the tails of the Gaussian distribution in CN and
AD class is done to account for the fact that some of the
CN subjects could be in pre-symptomatic stage of disease
progression and some of the biomarkers could still be nor-
mal in AD subjects. B and C) This is followed by iterative
estimation of Gaussian parameter optimization and Mixing
parameter optimization.
f(xj,i) = θ
E
i p(xj,i|µEi , σEi )+θ¬Ei p(xj,i|µ¬Ei , σ¬Ei )
= θEi p(xj,i|Ei) + θ¬Ei p(xj,i|¬Ei) (6)
θEi and θ
¬E
i are selected such that θ
E
i + θ
¬E
i = 1.
The mixing parameters and the Gaussian parame-
ters are optimized alternately, until convergence of
the mixing parameters. The initialization and opti-
mization strategy in GMM is illustrated in Figure 3.
The strategy of alternating between optimizing
for mixing parameter and optimizing for Gaussian
parameters in combination with the initialization
strategy and the subsequent constraints is different
from all previous versions of EBM and it will be
shown in Section 5 that this results in more accurate
central ordering of events in most cases.
3.2. Estimating a disease progression timeline
3.2.1. Estimating Subject-Specific Orderings
The PDF thus obtained is used for classifica-
tion of the biomarkers using a Bayesian classifier,
where the mixing parameters (θEi and θ
¬E
i ) are
used as the prior probabilities (p(Ei) and p(¬Ei)
respectively) when estimating posterior probabili-
ties for each biomarker. We assume these posterior
probabilities to be a measure of progression of a
biomarker. Thus, sj is established such that:
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sj 3 p(Esj(1)|xj,sj(1)) > p(Esj(2)|xj,sj(2)) >
... > p(Esj(N)|xj,sj(N)) (7)
However, the posterior probability is influenced
not only by progression of the biomarker value to
its abnormal state, but also by inherent variability
in normal and abnormal biomarker values across
subjects, and by measurement noise. Disentan-
gling measurement noise and inherent variability in
normal biomarker values from progression of the
biomarker to its abnormal state can only be done
based on longitudinal data. This makes sj a noisy
estimate.
3.2.2. Estimating a central ordering
Since the event ordering for each subject is es-
timated independently, any heterogeneity in dis-
ease progression is captured in the estimates of sj .
The central event ordering (S) is the mean of the
subject-specific estimates of sj . To describe the dis-
tribution of sj , we make use of a generalized Mal-
lows model. The generalized Mallows model is pa-
rameterized by a central (‘mean’) ordering as well
as spread parameters (analogous to the standard
deviation in a normal distribution). The central
ordering is defined as the ordering that minimizes
the sum of distances to all subject-wise orderings
sj . To measure distance between orderings, an of-
ten used measure is Kendall’s Tau distance (Huang
and Alexander, 2012). Kendall’s Tau distance be-
tween a subject specific event ordering (sj) and cen-
tral ordering (S) can be defined as:
K(S, sj) =
N−1∑
i=1
Vi(S, sj) (8)
where Vi(S, sj) is the number of adjacent swaps
needed so that event at position i is the same in
sj and S.
Since the estimates of sj are based on rankings
of posterior probabilities, it would be desirable to
penalize certain swaps more than others, based on
how close the posterior probabilities are to each
other. To this end, we introduce a probabilistic
Kendall’s Tau distance, which penalizes each swap
based on the difference in posterior probabilities of
the corresponding events.
K̂(S, sj) =
N−1∑
i=1
V̂i(S, sj) (9)
V̂i∀i ∈ [1, N − 1] is computed sequentially using
the following algorithm5:
Algorithm 1 Probabilistic Kendall Tau distance
between Subject-specific event orderings and cen-
tral event ordering
1: for i ∈ [1, N − 1] do
2: k ← s−1j (S(i))
3: if k > i then
4: V̂i(S, sj)←
∑k
l=i+1 pi − pl
5: Move sj(k) to position i and update sj
6: else
7: V̂i(S, sj)← 0
where pa is shortened notation for
p
(
Esj(a)|xj,sj(a)
)
.
This variant of Kendall’s Tau distance is quite
close to the weighted Kendall’s Tau distance de-
fined in the permutation space introduced in Ku-
mar and Vassilvitskii (2010). The difference stems
from the fact that since the probabilistic Kendall’s
Tau distance is between individual estimates and
a central-ordering, the penalization of each swap is
weighted asymmetrically as V̂i(S, sj) 6= V̂i(sj , S).
The optimum S is the one that minimizes∑
∀j K̂(S, sj). However, computing a global opti-
mum S based on subject-wise orderings is NP-hard.
Thus getting a good initial estimate of S is impor-
tant to ensure the estimated S is not a suboptimal
local optimum. In our implementation the initial
estimate of S is based on ordering θ¬Ei . The moti-
vation for this is discussed in Section 3.3. S was fur-
ther optimized based on the algorithm introduced
by Fligner and Verducci (1988) to estimate the
central ordering.
3.2.3. Estimating Event Centers
The S that has been derived in this manner, is
an estimate of the sequence in which the biomarkers
become abnormal during the progression of a dis-
ease. However, it falls short of being a disease time-
line, because it does not provide information about
the proximity of consecutive events. To address this
issue, we estimate distances between events by com-
puting the cost of adjacent swaps in the event or-
dering, as measured by summation of probabilistic
5The summation symbol in step 4 was missed accidentally
in Venkatraghavan et al. (2017).
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Kendall’s Tau distance over all subjects.
Γi+1,i =
∑
∀j
K̂(Si+1,i, sj)− K̂(S, sj) (10)
where Si+1,i is identical to S except for the swap
between events at locations i and i + 1, and Γi+1,i
is the cost of the swap. This represents the cost for
the central ordering to be Si+1,i instead of S. We
hypothesize that the closer the events i+1 and i are
to each other, the lower the swapping cost would be.
Hence we consider these costs to be proportional
to distance between events in terms of biomarker
progression.
To estimate the distance of the first biomarker
being abnormal (event) in S to a hypothetical
disease-free individual, we introduce a pseudo-event
which becomes abnormal at the beginning of the
disease timeline and hence is abnormal for all the
subjects in the database i.e. p (E0|xj,0) = 1 ∀j.
Similarly, we introduce another pseudo-event which
becomes abnormal at the end of the disease time-
line and hence is normal for all the subjects in the
database i.e. p (EN+1|xj,N+1) = 0 ∀j. We scale
Γi+1,i∀i ∈ [0, N ] such that
∑
Γi+1,i = 1. Event
center (λk) of event k in S for k > 0, is computed
as follows:
λk =
k−1∑
i=0
Γi+1,i (11)
In fact, the concept of event centers can also be
extended to Fonteijn’s EBM by computing the cost
of adjacent swaps in the event ordering as the dif-
ference in log-likelihoods as follows:
Γi+1,i = log (p(X|S))− log (p(X|Si+1,i)) (12)
Extension of this concept to Huang’s EBM is not
straightforward and is beyond this paper’s scope.
The set of event centers λ1,2,...,N , will henceforth
be referred to as Λ. This results in a disease time-
line, with S giving information about the order of
progression of biomarkers and Λ giving information
about the event centers in this timeline.
3.3. Patient Staging
Once the central ordering of events (S) and event
centers (Λ) have been determined, we propose a pa-
tient staging algorithm where a patient stage (Υj)
is interpreted as an expectation of λk with respect
to the conditional distribution p(k|S,Xj). Thus,
Υj can be written as given below:
Υj =
∑N
k=1 λkp(k|S,Xj)∑N
k=1 p(k|S,Xj)
(13)
Multiplying p(S,Xj) in both numerator and de-
nominator and using the chain rule of probability
results in:
Υj =
∑N
k=1 λkp(k, S,Xj)∑N
k=1 p(k, S,Xj)
(14)
Using chain rule of probability, we can write
p(k, S,Xj) as:
p(k, S,Xj) = p(Xj |k, S)p(k, S) (15)
If we assume a uniform distribution of p(k|S)
and p(S) as in Fonteijn et al. (2012), p(k, S,Xj)
becomes equal to p(Xj |k, S), which was used for
patient staging in Fonteijn’s EBM as discussed in
Section 2. However we use prior knowledge in order
to define a more informative distribution p(k, S):
p(k, S) =
∏k
i=1 θ
E
S(i)
∏N
i=k+1 θ
¬E
S(i)
Z
(16)
where Z is a normalizing factor, chosen so as to
make this a probability. This choice of p(k, S) can
be justified because biomarkers which become ab-
normal earlier in the disease process are more likely
to have a higher value of θEi than the biomarkers
which become abnormal later. Hence it is far more
likely to have a central-ordering based on ascend-
ing values of θ¬Ei than an ordering with ascending
values of θEi . It should be noted that, the choice
of p(k, S) is not unique. For example, it could also
be any n-th power of the above equation ∀n > 0.
Thus, from Equations 15, 16 and 4, we get:
p (k, S,Xj) ∝
k∏
i=1
p
(
xj,S(i)|ES(i)
)
θES(i)×
N∏
i=k+1
p
(
xj,S(i)|¬ES(i)
)
θ¬ES(i) (17)
Using the above value of p (k, S,Xj) in Equa-
tion 14, results in continuous patient stages.
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4. Experiments
This section describes the experiments per-
formed to benchmark the accuracy of the proposed
DEBM algorithm and compare it with state-of-
the-art EBM methods. The EBM methods used
for comparison in these experiments are Huang’s
EBM (Huang and Alexander, 2012) and the variant
of Fonteijn’s EBM that is suited for AD disease pro-
gression modeling (Young et al., 2014). The source
code for DEBM and Fonteijn’s EBM, with differ-
ent mixture modeling techniques and patient stag-
ing techniques discussed in this paper have been
made publicly available online under the GPL 3.0
license: https://github.com/88vikram/pyebm/.
The source code for Huang’s EBM used in our
experiments was provided by the authors of the
method.
For brevity, Fonteijn’s EBM and Huang’s EBM
will henceforth be referred to as FEBM and HEBM,
respectively. The mixture model used with an EBM
model (as the one described in Section 3.1) will be
denoted by a subscript. For example, FEBM with
the Gaussian mixture model proposed in Young
et al. (2014) will be referred to as FEBMay. The
Gaussian mixture model optimization techniques
in Huang and Alexander (2012), Venkatraghavan
et al. (2017) and the one introduced in this paper
will be denoted with subscripts ‘jh’, ‘vv1’ and ‘vv2’
respectively.6
Data used in the experiments were obtained
from the Alzheimers Disease Neuroimaging Initia-
tive (ADNI) database (adni.loni.usc.edu) 7 . We be-
gin with the details of the experiments performed
on ADNI data to estimate the event ordering in
Section 4.1. Since the ground-truth event ordering
6Mixture model ‘ay’ optimizes for Gaussian and mixing
parameters together. Initialization of Gaussian parameters
for optimization is done without rejecting the overlapping
part of Gaussians in CN and AD classes. ‘vv1’ also optimizes
for Gaussian and mixing parameters together (although with
much stricter bounds) but the initialization of Gaussian pa-
rameters is similar to the one in this paper. ‘jh’ couples
mixture modeling with estimation of subject-specific order-
ing to estimate a combined optimum solution.
7The ADNI was launched in 2003 as a public-private part-
nership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to mea-
sure the progression of mild cognitive impairment (MCI) and
early Alzheimers disease (AD). For up-to-date information,
see www.adni-info.org.
is unknown for clinical datasets, we resort to us-
ing the ability of patient staging to classify AD and
CN subjects, as an indirect way of measuring the
reliability of the event ordering. We also measure
the accuracy of event ordering and relative distance
between events more directly by performing exten-
sive experiments on synthetic data simulating the
progression of AD. The details of these experiments
are given in Section 4.2.
4.1. ADNI Data
We considered 1737 ADNI subjects (417 CN,
978 MCI and 342 AD subjects) who had a struc-
tural MRI (T1w) scan at baseline. The T1w scans
were non-uniformity corrected using the N3 algo-
rithm (Tustison et al., 2010). This was followed
by multi-atlas brain extraction using the method
described in Bron et al. (2014). Multi-atlas seg-
mentation was performed (Hammers et al., 2003;
Gousias et al., 2008) using the structural MRI scans
to obtain a region-labeling for 83 brain regions in
each subject using a set of 30 atlases. Probabilistic
tissue segmentations were obtained for white mat-
ter, gray matter (GM), and cerebrospinal fluid on
the T1w image using the unified tissue segmen-
tation method (Ashburner and Friston, 2005) of
SPM8 (Statistical Parametric Mapping, London,
UK). The probabilistic GM segmentation was then
combined with region labeling to obtain GM vol-
umes in the extracted regions. We also downloaded
CSF (Aβ1−42 (ABETA), TAU and p-TAU) and cog-
nitive score (MMSE, ADAS-Cog) values from the
ADNI database, making the total number of fea-
tures equal to 88.
The features TAU and p-TAU were transformed
to logarithmic scales to make the distributions less
skewed. GM volumes of segmented regions were
regressed with age, sex and intra-cranial volume
(ICV) and the effects of these factors were subse-
quently corrected for, before being used as biomark-
ers. The effect of age and sex was regressed out of
CSF based features, whereas effects of age, sex and
education was regressed out of cognitive scores.
We retained 52 biomarkers (GM volume based
biomarkers of 47 regions, 3 CSF and 2 cognitive
scores) having significant differences between CN
and AD subjects using Student’s t-test with p <
0.005, after Bonferroni correction. These biomarker
values were used to perform two sets of experi-
ments.
Experiment 1(a): A subset of 7 biomarkers in-
cluding the 3 CSF features, MMSE score, ADAS-
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Cog score, gray matter volume of the hippocam-
pus (combined volume of left and right hippocampi)
and gray matter volume in whole brain was created.
Event ordering of these 7 biomarkers was inferred
using DEBM. We studied the positional variance
of central ordering and variance of event centers
inferred by DEBM by creating 100 bootstrapped
samples of the data.
Experiment 1(b): The Biomarkers were
ranked based on their aforementioned p-value and
the above experiment was repeated with top 25 and
top 50 biomarkers to investigate if the event-centers
estimated for the subset of Biomarkers used in Ex-
periment 1(a), remain comparable to the ones esti-
mated in Experiment 1(a).
Experiment 2: As an indirect way of measur-
ing the accuracy of the estimated event ordering, we
use patient staging based on the estimated event or-
derings as a way to classify CN and AD subjects in
the database. 10-fold cross validation was used for
this purpose. AUC measures were used to measure
the performance of these classifications and thus
indirectly hint at the reliability of the event order-
ing based on which the corresponding patient stag-
ing were performed. We used varying number of
biomarkers (ranked based on their p-value) ranging
from 5 to 50 in steps of 5 for this experiment. We
used the methods FEBMay, HEBMjh, DEBMvv1
and DEBMvv2 for inferring the ordering. Patient
staging was done based on the methods described
in their respective papers. Since the earlier version
of DEBM (Venkatraghavan et al., 2017) had not
introduced a patient staging method, we use the
patient staging method described in this paper for
evaluating the method.
4.2. Simulation Data
We used the framework developed by Young et al.
(2015a) for simulating cross-sectional data consist-
ing of scalar biomarker values for CN, MCI and AD
subjects. In this framework, disease progression in
a subject is modeled by a cascade of biomarkers be-
coming abnormal and individual biomarker trajec-
tories are represented by a sigmoid. The equation
for generating biomarker values for different sub-
jects is given below:
xj,i(Ψ) =
Ri
1 + exp(−ρi(Ψ− ξj,i)) + βj,i (18)
Ψ denotes disease stage of a subject which we
take to be a random variable distributed uniformly
throughout the disease timeline. ρi signifies the rate
of progression of a biomarker, which we take to be
equal for all subjects. ξj,i denotes the disease stage
at which the biomarker becomes abnormal. βj,i de-
notes the value of the biomarker when the subject is
normal and Ri denotes the range of the sigmoidal
trajectory of the biomarker, which we take to be
equal for all subjects.
In our experiments, βj,i and ξj,i ∀j are as-
sumed to be random variables with Normal dis-
tribution N(µβi ,Σβi) and N(µξi ,Σξi) respectively.
µβi is equal to the mean value of the corresponding
biomarker in the CN group of the selected ADNI
data. Ri is equal to the difference between the
mean values of the biomarker in the CN and AD
groups of the selected ADNI data. Σβi represents
the variability of biomarker values in the CN group.
We consider a relative scale for Σβi , where 1 refers
to the observed variation among the CN subjects
in ADNI data. Variation in ξj,i is controlled by
Σξi and results in variation in ordering among sub-
jects in population and could be seen as a param-
eter controlling the disease heterogeneity within a
simulated population. Σξi ∀i is varied in multiples
of ∆ξ, where ∆ξ is the average difference between
adjacent µξi . µξi refers to the event centers of var-
ious biomarkers. The set of µξi∀i will collectively
be referred to as Λgt and they will be used to assess
the accuracy of estimated event centers (λi).
The parameters in the simulation framework that
could have an effect on the performance of EBMs
are Σβi , µξi , Σξi , and ρi. Apart from this, the num-
ber of subjects (M) and the number of biomarkers
(N) in the dataset could also have an effect on the
performance of EBMs. Using this simulation frame-
work, we study the effect of the aforementioned pa-
rameters on the ability of different variants of EBM
algorithms to accurately infer the ground-truth cen-
tral ordering in the population. Change in µβi re-
sults only in a translational effect on biomarker val-
ues and change in Ri results only in a scaling effect
on biomarker values. These factors do not affect
the performance of the EBMs and hence were not
evaluated in our experiments.
Performance of an EBM method can be measured
using error in estimation of either S or Λ. Error in
estimating S (S) will henceforth be referred to as
‘ordering error’ whereas the error in estimating Λ
(Λ) will henceforth be referred to as ‘event-center
9
error’. S is computed using the following equation:
S =
K(S, Sgt)(
N
2
) (19)
where Sgt is the ground truth ordering. S is effec-
tively a normalized Kendall’s Tau distance between
S and Sgt. The normalization factor for
(
N
2
)
, was
chosen to make the accuracy measure interpretable
for different number of biomarkers.
For comparing Λ and Λgt, Λ were scaled and
translated such that the mean and standard devi-
ation of Λ were equal to that of Λgt. This is done
because we are only interested in evaluating the er-
rors in estimating relative distance between events
and not the absolute position of event-centers. The
choice of scale in event-centers are arbitrary and
the chosen scale for the estimated event-centers was
based on pseudo-events, which need not necessarily
coincide with the simulation framework’s ground-
truth event-centers.
Λ =
∑
∀i
|λsti − µξi | (20)
where λsti is the scaled and translated version of λi.
As mentioned before, the factors that can have
an effect on the performance of EBMs are Σβi , µξi ,
Σξi , ρi, M and N . In each of the following 5 ex-
periments, a few of these factors were varied while
the others were set to their default values. The
default value for Σβi was taken to be 1 as this cor-
responds to the observed variation among CN sub-
jects in ADNI. µξi were spaced equidistantly, i.e.,
µξi+1 − µξi = 1/(N + 1). As the actual variation in
event centers among different subjects is not known
in a clinical dataset, the default value of Σξi was
taken to be 2∆ξ. For the sake of simplicity of nota-
tion ∆ξ will be omitted henceforth, and the values
of Σξi are implicitly in multiples of ∆ξ. ρi was con-
sidered to be equal for all biomarkers by default.
The default values for M and N were 1737 and 7
respectively, mimicking the dataset used in Exper-
iment 1(a). For each simulation setting, 50 repeti-
tions of simulation data were created and used for
benchmarking the performance of EBMs on syn-
thetic data.
Experiment 3: The first simulation experi-
ment was performed to study the effect of Σβ ∈
[0.2, 1.8] and Σξ ∈ [0, 4], varying one at a time
while keeping the other at its mean value. The
S of FEBMay, FEBMvv2, HEBMjh, HEBMvv2,
DEBMvv1 and DEBMvv2 were determined.
Experiment 4: The above experiment was re-
peated for DEBMvv2 and FEBMvv2 and the Λ were
measured for the two methods.
Experiment 5: This experiment was performed
to study the effect of a non-uniform distribution of
µξi . Σβ and Σξ combinations of (0.6, 1), (1.0, 2),
(1.4, 3) and (1.8, 4) were tested to study their ef-
fect in non-uniformly spaced biomarkers. S of
DEBMvv2, FEBMvv2 and HEBMvv2 were mea-
sured. Additionally, Λ of DEBMvv2 and FEBMvv2
were measured. To also study the effect of unequal
rates of progression of biomarkers (ρi), the above
experiment was performed once with equal ρi for
all biomarkers and once when they were unequal.
The experiment with unequal biomarker rates had
the same mean biomarker progression rate as the
the experiment with equal biomarker rates. The
progression rates of different biomarkers has been
included as supplementary material (Figure S1).
Experiment 6: This experiment was performed
to study the influence of the number of subjects
(M). M was varied from 100 to 2100 in steps of
200. S of DEBMvv2, FEBMvv2 and HEBMvv2 were
measured. DEBMvv2 and FEBMvv2 were also as-
sessed based on Λ.
Experiment 7: This experiment was performed
to study the influence of the number of biomarkers
(N). N was varied from 7 to 52 in steps of 5. In
each random generation of a dataset, we randomly
selected (with replacement) the biomarkers to be
used in the iteration. This was done to study the
effect of N on the EBM models and separate it
from the effect of adding weaker biomarkers. S
of DEBMvv2, FEBMvv2 and HEBMvv2 were mea-
sured. DEBMvv2 and FEBMvv2 were also assessed
based on Λ.
5. Results
5.1. ADNI Data
Experiment 1: Figures 4, 5 and 6 show the
positional variance and event-center variance ob-
tained using DEBMvv2 with 7, 25 and 50 number
of events respectively. Table 1 shows the abbrevia-
tions used in Figures 5 and 6 along with their full
names. Figure 7 maps the colors used for y-axis
labels of Figures 5 and 6 to different lobes in the
brain.
It can be seen from Figure 4 (left) that CSF-
based biomarkers ABETA becomes abnormal be-
fore MMSE and CSF-based p-TAU. This is followed
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Figure 4: Experiment 1(a): DEBMvv2 with 7 Events. The positional variance diagram (left) shows the uncertainty in estimating
the central event ordering. The event-center variance diagram (right) shows the standard error of estimated event centers. These
were measured by 100 repetitions of bootstrapping.
Figure 5: Experiment 1(b): DEBMvv2 with 25 Events. The positional variance diagram (left) shows the uncertainty in
estimating the central event ordering and the event-center variance diagram (right) shows the standard error of estimated
event centers. These were measured by 100 repetitions of bootstrapping. The event centers of the biomarkers used in Figure 4
are marked in red. Table 1 shows the full forms of the abbreviations used in the y-axis labels. Figure 7 maps the colors used
for y-axis labels to different lobes in the brain.
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Figure 6: Experiment 1(b): DEBMvv2 with 50 Events. Positional variance diagram (left) shows the uncertainty in estimating
the central event ordering and event center variance diagram (right) shows the standard error of estimated event-centers. These
were measured by 100 repetitions of bootstrapping. The event-centers of the biomarkers used in Figure 4 are marked in red,
whereas the ones used in Figure 5 are marked in blue. Table 1 shows the full forms of the abbreviations used in the y-axis
labels. Figure 7 maps the colors used for y-axis labels to different lobes in the brain.
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Abbreviation Full name
L Left
R Right
PHA Parahippocampalis et Ambiens
Med. Medial
Inf. Inferior
Sup. Superior
Temp. Temporal
Pos. Posterior
Lat. Lateral
Ant. Anterior
OT Occipitotemporal
Cent. Central
Mid. Middle
Rem. Remainder
Occ. Occipital
PS Pre-subgenual
Table 1: Abbreviations used in Figures 5 and 6 along with
their full names (Hammers et al., 2003).
Figure 7: Legend for the colors used in Figures 5 and 6. The
colors map different biomarker labels to lobes in the brain.
by ADAS13, Hippocampal volume, TAU and whole
brain volume. However Figure 4 (right) shows that
the event centers for MMSE, ADAS13, p-TAU are
close to each other and so are the event-centers of
TAU and hippocampus volume. The event associ-
ated with the TAU biomarker seems closer to the
whole brain volume event as they are in positions
6 and 7 of Figure 4 (left). However, the centers
of these two events are quite far apart in Figure 4
(right) and the p-TAU event (position 2) is closer
to the TAU event than whole brain volume event.
As the number of biomarkers increases, the vari-
ation in the positions also increases considerably, as
seen in Figures 5 (left) and 6 (left). The event cen-
ters of the biomarkers used in Experiment 1(a) re-
main fairly consistent (±0.05) in Experiment 1(b).
It can also be seen that biomarkers with lower p-
values (biomarkers included in the model with 50
biomarkers and not in the model with 25 biomark-
ers), have larger variance in their event-center esti-
mation.
Experiment 2: Figure 8 (a) shows the mean
AUC when using patient stages for classifying CN
versus AD subjects using DEBM and other vari-
ants of EBM methods. It can be observed that the
AUC of all the methods decreases as the number of
events increases. The proposed method DEBMvv2
followed by the proposed patient staging algorithm
outperforms all the existing EBM variants consis-
tently.
Figure 8 (b) shows the distribution of patient
stages for the whole population when the most
significant 25 features were given as input to
DEBMvv2. This graph shows a peak at disease
stage 0 dominated by CN and MCI non-converters,
which shows that these subjects are not progress-
ing towards AD. The non-zero lower disease stages
are dominated by CN subjects and MCI non-
converters, whereas MCI converters8 and the sub-
jects with AD have higher disease stages.
5.2. Simulation Data
Experiment 3: Figures 9 shows the ordering
errors of DEBM, FEBM and HEBM models with
different mixture models as Σβ and Σξ increase.
The error-bars depict mean and standard deviation
of the errors obtained in 50 repetitions of simula-
tions. It can be seen that the proposed optimiza-
tion technique improves the performance of all three
EBM models. The change is particularly evident
when comparing the performance of FEBMvv2 and
FEBMay.
It can also be seen that FEBMvv2 performs
slightly better than DEBMvv2 when Σξ is low, but
as Σξ increases, the performance of FEBMvv2 de-
grades significantly. The performance of HEBM
is almost always worse than its FEBM or DEBM
counterpart.
Experiment 4: Figure 10 (a) and (b) shows
the event-center errors in DEBMvv2 and FEBMvv2
as the variability in population (Σβ) and disease
heterogeneity (Σξ) increases respectively. It should
be noted from Figure 9(b) and Figure 10 (b) that,
even when the FEBMvv2 gets the ordering more
accurately than DEBMvv2 in cases of low Σξ, the
event-center estimation of DEBMvv2 is on par with
or better than its FEBM counterpart.
Figure 10 (c) shows the estimated event-center
locations for Σβ = 1.0 and Σξ = 2 and the ground
truth event-centers.
Experiment 5: Figure 11 (a) shows the ordering
errors of DEBMvv2, FEBMvv2 and HEBMvv2 as Σβ
8MCI converters are subjects who convert to AD within
3 years of baseline measurement
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Figure 8: Experiment 2: In (a) we see the variation of AUC
with respect the number of biomarkers used for building the
model using DEBM, when the obtained patient stages were
used for classification of CN versus AD subjects. The AUC
measure was obtained using 10-fold cross-validation. In (b)
we see the frequency of occurrence of subjects in different
disease stages, when the most significant 25 features were
given as input to DEBMvv2 for inferring the ordering as well
as for patient staging.
and Σξ increase, when the ground-truth event cen-
ters (µξi) are non-uniformly spaced. The spacing
of µξi can be observed in Figure 11 (b), where the
ground truth event-centers as well as the estimated
event-centers of DEBMvv2 and FEBMvv2 are shown
for Σβ = 1.0 and Σξ = 2. It can be observed that
the estimated event-centers for DEBMvv2 are much
closer to the ground-truth event centers than those
of FEBMvv2 and also have a much lower variance
over different iterations of simulations.
Figure 11 (c) shows the ordering errors as Σβ
and Σξ increases, when µξi is non-uniformly spaced
and ρi is not identical for all biomarkers. It should
also be noted that the mean of ρi over all i has not
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Figure 9: Experiment 3: Ordering errors of DEBMvv1,
DEBMvv2, FEBMay, FEBMvv2, HEBMjh and HEBMvv2 for
50 repetitions of simulations. Figure (a) shows the ordering
error as a function of variability in population (Σβ). Fig-
ure (a) shows the ordering error as a function of variation
in ordering (Σξ). Error bars in (a) and (b) represent stan-
dard deviations over the 50 repetitions. Figure (c) shows the
legend for the plots in (a) and (b).
changed between (a) and (c). The variation of er-
rors in (c) is quite similar to the one in (a). This
shows that performance of EBM methods that are
reported in other experiments (where ρi is equal
for all biomarkers) can be expected to not deteri-
orate in the more realistic scenario of ρi not being
equal for all biomarkers. The event-center variance
for Σβ = 1.0 and Σξ = 2 for the case of unequal
ρi is very similar to (b) and has been included as
supplementary material (Figure S2).
14
Σβ
E
v
en
t-
C
en
te
r
E
rr
o
r
(a)
Σξ
E
v
en
t-
C
en
te
r
E
rr
o
r
(b)
Disease Stage
(c)
Figure 10: Experiment 4: Figures (a) and (b) show the
event-center errors of DEBMvv2 and FEBMvv2 as a func-
tion of Σβ and Σξ respectively. Figure (c) shows the es-
timated event-center locations for both methods as well as
the ground-truth event centers. Error bars in (a), (b) and
(c) represent standard deviation over 50 repetitions of sim-
ulation.
Experiment 6: Figure 12 shows the mean
ordering errors of DEBMvv2, FEBMvv2 and
HEBMvv2 as a function of number of subjects in
the dataset on one vertical axis and shows the mean
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Figure 11: Experiment 5: Figures (a) and (c) show the or-
dering errors of DEBMvv2, FEBMvv2 and HEBMvv2 when
µξi are not uniformly distributed. Σβ and Σξ increase as
we move from left to right. Figure (a) shows the errors in
the case when ρi are identical for all the biomarkers whereas
(c) shows the errors when ρi are different. Figure (b) shows
the non-uniform µξi as well as the estimated event-centers
by DEBMvv2 and FEBMvv2 for the case of ρi being equal.
Error bars in (a), (b) and (c) represent standard deviation
over 50 repetitions of simulation.
event-center errors of DEBMvv2 and FEBMvv2 on
the other vertical axis. As expected, the mod-
els perform better as the number of subjects in-
creases. DEBMvv2 is slightly better at inferring
the central ordering than FEBMvv2 when the num-
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Figure 12: Experiment 6: Ordering errors of DEBMvv2,
FEBMvv2 and HEBMvv2 as a function of number of subjects
(M) in the dataset. It also shows the event-center errors of
DEBMvv2 and FEBMvv2 as a function of M .
ber of subjects is very low, but FEBMvv2 outper-
forms DEBMvv2 when the number of subjects is
higher. However, when the accuracy of event cen-
ters are considered, DEBMvv2 consistently outper-
forms FEBMvv2.
Experiment 7: Figure 13 shows the mean
ordering errors of DEBMvv2, FEBMvv2 and
HEBMvv2 as a function of the number of events
(biomarkers) in the dataset on one vertical axis and
shows the mean event-center errors of DEBMvv2
and FEBMvv2 on the other vertical axis. The
biomarkers were selected randomly after replace-
ment so that the chances of selecting a bad
biomarker remain equal as the number of events
increases. It can be noted that the errors of the
EBM models increase as the number of events in-
creases initially, even when the average quality of
biomarkers remains the same. However the errors
stabilize beyond a certain point and do not increase
any more.
6. Discussion
We proposed a novel discriminative EBM frame-
work to estimate the ordering in which biomark-
ers become abnormal during disease progression,
based on a cross-sectional dataset. The proposed
framework outperforms state-of-the-art EBM tech-
niques in estimating the event ordering. We also
introduced the concept of relative distance between
event-centers, which enables creating a disease pro-
gression timeline. This in turn led to the develop-
ment of a new continuous patient staging mecha-
Number of Events (N)
Figure 13: Experiment 7: Ordering errors of DEBMvv2,
FEBMvv2 and HEBMvv2 as a function of number of events
(N) in the dataset. It also shows the event-center errors of
DEBMvv2 and FEBMvv2 as a function of N .
nism. In addition to the framework, we also pro-
posed a novel probabilistic Kendall’s Tau distance
metric and a robust biomarker distribution estima-
tion algorithm. In this section, we discuss different
aspects of the proposed algorithm.
6.1. Event Centers
Event-centers capture relative distance between
events. This helps in creating the disease progres-
sion timeline from an ordering of events. Event cen-
ters are an intrinsic property of the biomarker used,
for the selected population. This was observed in
Experiment 1(b) where the event-centers estimated
using DEBMvv2 remained fairly consistent (±0.05)
across models using different number of biomarkers.
The estimated disease progression timeline can
be used for inferring progression of the disease, with
the event centers being synonymous to milestones
of progression. A strict quantization of position
in ordering of events (as reported in Oxtoby and
Alexander (2017), Venkatraghavan et al. (2017),
Young et al. (2015a), Young et al. (2014), Fonteijn
et al. (2012)) in the positional variance diagram can
sometimes be non-intuitive in terms of inferring ac-
tual progression of the disease. This was seen in
Experiment 1(a), where the event center variance
diagram showed that the TAU event (at position 6)
was closer to the p-TAU event (at position 2) than
the whole brain event (position 7).
The approach of scaling the event-centers be-
tween [0, 1] has its advantages and disadvantages.
The advantage of such a scaling is that models
built on different biomarkers, but within the same
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population, remain comparable. For example, a
model built with CSF and MRI based biomarkers
can be compared with a model built on MRI based
biomarkers alone, as the event-centers of MRI based
biomarkers would approximately be the same. On
the other hand, the position of the first event re-
lies heavily on the number of ‘true’ controls in
the dataset (CN subjects who are not in an early
asymptomatic stage of the disease). This is the
result of introducing pseudo-events for scaling the
events-centers.
Comparison of the event centers across differ-
ent datasets with different number of controls (al-
beit with the same biomarkers) can be done in
three ways. Event-centers can be scaled and trans-
lated such that the mean and standard deviation
of event centers computed across different datasets
are the same (similar to the comparisons between
estimated and ground-truth event centers in this
paper). Alternately, the event center of the first
biomarker can be set as 0 and the event center of
the last biomarker can be set to 1, before compar-
ison. Lastly, in a dataset where controls (i.e., sub-
jects whose biomarker values are all normal) can be
easily identified, it would be better to exclude them
for event-center computation.
The estimated event centers have a good corre-
lation with the groundtruth disease timeline. This
can be seen in the simulation experiments with and
without uniform spacing of events (experiments 4
and 5). It must however be noted that, the disease
stages Ψ of the simulated subjects were distributed
uniformly throughout the disease timeline. If the
distribution is not uniform, we expect it to have an
effect on the estimation of event centers. Analyz-
ing the exact effect of such non-uniform distribu-
tions on the estimation of event centers and ways
to estimate event centers invariant to the distribu-
tion of subjects on the disease timeline could be an
interesting extension of the current work.
Experiment 5 also showed that different biomark-
ers having different rates of progression does not
degrade the performance of EBM models, as long
as the mean rate of progression is the same. We
did not perform an experiment to benchmark the
accuracies by changing the mean rates of progres-
sion of biomarkers. This experiment was already
performed in Young et al. (2015b) and it was ob-
served that FEBM ordering error decreases as the
mean rates of progression increase.
FEBM assumes that the disease is homogeneous,
as it expects all the subjects in the dataset to fol-
low the same ordering. When the variability of or-
dering in different subjects is low, FEBM with the
proposed mixture model ‘vv2’ outperforms DEBM
with the proposed mixture model. This can be seen
in the results of Experiments 3, 5 and 6. When the
assumption becomes too restrictive, DEBM with
the proposed mixture model outperforms FEBM.
Even when the assumption holds true, estimation
of event-centers with DEBM is more accurate than
with FEBM.
6.2. Patient Staging
Existing patient staging algorithms discretize the
patient stages based on event position, whereas the
patient staging algorithm introduced in this paper
takes relative distance between events into consid-
eration while staging new subjects. This makes pa-
tient stages more useful for diagnosis and progno-
sis as they correlate more with the actual disease
progression timeline. Discrete patient stages with-
out considering the event centers could diminish the
prognosis value of the obtained stages.
The cross-validation experiment on ADNI data
(Experiment 2) showed that the CN and AD sub-
jects are well separated after patient staging and
that the AUC of the proposed method is better than
that of the state-of-the-art EBM techniques. It also
showed that MCI converters and non-converters are
well separated after patient staging, without explic-
itly training the model to achieve this.
It must however be noted that even though het-
erogeneity of the disease was considered while infer-
ring the central ordering, it was not considered for
patient staging. Inferring multiple central orderings
corresponding to different disease subtypes (Young
et al., 2015a) and staging patients on one of these
central orderings may help us overcome this draw-
back. Patient staging with respect to subject-
specific orderings (as done in HEBM) can also be
considered when extending DEBM for longitudinal
data, where the subject-specific orderings might be
estimated with higher confidence.
6.3. Scalability of Event-Based Models
Understanding the progression of several imaging
and non-imaging biomarkers after disease onset is
important for assessing the severity of the disease.
Hence it is desirable to have a model scalable to a
large number of biomarkers. FEBM and DEBM are
scalable to large number of events, whereas HEBM
is not. This was seen in the simulation experiment
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on varying number of events (Experiment 7), where
the errors of FEBM and DEBM increased asymp-
totically with increasing number of events. The or-
dering errors of HEBM reached 0.5 for large number
of events, which is equivalent to random prediction.
In Experiment 6, we observed that the errors
of the EBMs decrease with increasing number of
subjects in the dataset. We hence expect FEBM,
DEBM and HEBMvv2 to be scalable to a large num-
ber of subjects.
The performance of HEBMjh is seen to be consis-
tently worse than FEBMay in Experiment 3. This
is in contrast with the findings of Venkatragha-
van et al. (2017), where HEBMjh performed bet-
ter than FEBMay when the number of biomarkers
used were 7, while it performed worse when the
number of biomarkers used were 42. One of the
key differences between the experiment performed
in Venkatraghavan et al. (2017) and Experiment 3
is the number of subjects in the simulation dataset.
While the previous study considered 509 subjects,
Experiment 3 considered 1737 subjects. HEBMjh
jointly estimates the subject-specific orderings of
all the subjects and the mixture model to represent
the biomarkers in different diagnostic groups. We
think that while the joint estimation was good for
low number of subjects, increasing the number of
subjects had an adverse effect on the convergence
of the algorithm. Hence HEBMjh is not scalable to
a large number of subjects.
We decoupled the mixture model and estimation
of subject-specific orderings in HEBMvv2 (Experi-
ments 3, 5, 6 and 7). This made HEBM more scal-
able as it improved the results in Experiment 3 with
1737 subjects, but the decoupling had an adverse
effect on the algorithm when the number of subjects
was low, as seen in Experiment 6, where HEBMvv2
performs worse than FEBMvv2 even when the num-
ber of subjects was low.
FEBM and HEBM are generative approaches for
estimating the central ordering. Our results suggest
that HEBM is not very scalable. Although FEBM
is scalable, the assumptions made in FEBM are too
restrictive for heterogeneous disease such as AD.
DEBM is a discriminative approach to event-based
modeling, which is both scalable and can robustly
estimate central ordering even when the disease is
heterogeneous.
6.4. The Mixture Model
The optimization technique for the Gaussian
mixture model that is presented in this paper de-
couples the optimization of Gaussian parameters
and mixing parameters. When the Gaussians of the
pre-event and post-event classes are highly overlap-
ping, the optimum mixing parameter changes a lot
even for small changes in the Gaussian parameters.
By decoupling the optimizations for Gaussian pa-
rameters and mixing parameters, we get more sta-
ble mixing parameters. This helps in improving the
accuracy of all EBMs. This was observed in Exper-
iment 3.
6.5. The Importance of Good Biomarkers
Quality of biomarkers plays a huge role in the ac-
curacy of the EBMs. This was seen in Experiment
7, where the mean error value for 7 biomarkers was
considerably higher than the mean error value with
the same number of biomarkers in Experiment 4
(for the same Σβ and Σξ parameters). The ob-
served difference can be explained by the choice of
the biomarkers used in those experiments. While
the biomarkers chosen in Experiment 7 was at ran-
dom, the ones chosen in Experiment 4 were the 7
best biomarkers.
6.6. Interpretation of model results on ADNI
Experiment 1(a) showed that CSF biomarkers
ABETA and p-TAU are one of the first biomarkers
that become abnormal in AD, which is in agreement
with Jack’s hypothetical model (Jack Jr. et al.,
2013). The event centers of Hippocampus volume
and TAU are quite close to each other as well, which
is also in agreement with the current understand-
ing of the disease (de Souza et al., 2012). However,
MMSE and ADAS biomarkers are seen to become
abnormal quite early in the disease as well, which is
not in agreement with the hypothetical model. This
could suggest that functional abnormality starts be-
fore structural abnormality. It could also be be-
cause of the fact that we included everyone in ADNI
baseline measurement, for estimating the ordering.
Subjects with MCI may not necessarily be progress-
ing towards AD and including these subjects could
have an effect on inferring the ordering.
Nucleus accumbens right and left are the first
biomarkers to become abnormal as seen in Fig-
ure 7. This was also observed by Young et al.
(2017). However, the large standard error of the
event centers for the events before ABETA sug-
gests that the exact position of those events are
unreliable. Experiment 1(b) showed that weak
biomarkers (biomarkers excluded in Figure 5, but
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included in Figure 6) could lead to greater uncer-
tainty in event centers. This can be explained by
the fact that weak biomarkers are the ones where
there is a lot of overlap between the Gaussians of
pre-event and post-event classes. Small variation
in the sampling population during bootstrapping
leads to large changes in the parameters estimated
in the mixture modeling step of the algorithm. It
also showed that majority of the early structural
biomarkers are from Temporal lobe, followed by
Central structures, Frontal lobe, Parietal lobe and
Occipital lobe.
7. Conclusion
We proposed a new framework for event-based
modeling, called discriminative event-based model-
ing (DEBM), which includes a new optimization
strategy for Gaussian mixture modeling, a new
paradigm for inferring the mean ordering, a way
for estimating the proximity of events in the or-
der to create a disease progression timeline, and a
new way of staging patients that uses these rela-
tive proximities of events while placing new sub-
jects on the estimated timeline. The source code
for DEBM and FEBM was made publicly avail-
able online under the GPL 3.0 license: https:
//github.com/88vikram/pyebm/.
We applied the DEBM framework to a set of 1737
subjects from the baseline ADNI measurement, and
also performed an extensive set of simulation exper-
iments verifying the technical validity of DEBM.
The experiment on ADNI data illustrated a num-
ber of advantages of the new approach. Firstly,
we showed that strict quantization of position in
ordering of events in the positional variance dia-
gram can sometimes be non-intuitive in terms of
inferring actual progression of a disease. Secondly,
we showed that the patient staging based on the
proposed approach separates CN and AD group of
subjects much better than the previous EBM mod-
els. Thirdly, we showed that the patient staging can
be used to identify individuals at-risk of developing
AD as the MCI converters and non-converters were
well-separated. Staging patients based on the esti-
mated disease progression timeline can thus make
computer-aided diagnosis and prognosis more ex-
plainable. The results of these experiments are en-
couraging and suggest that DEBM is a promising
approach to disease progression modeling.
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